HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study.

BACKGROUND There are few data on the epidemiology of primary HIV-1 drug resistance after the roll-out of antiretroviral treatment (ART) in sub-Saharan Africa. We aimed to assess the prevalence of primary resistance in six African countries after ART roll-out and if wider use of ART in sub-Saharan Africa is associated with rising prevalence of drug resistance. METHODS We did a cross-sectional study in antiretroviral-naive adults infected with HIV-1 who had not started first-line ART, recruited between 2007 and 2009 from 11 regions in Kenya, Nigeria, South Africa, Uganda, Zambia, and Zimbabwe. We did population-based sequencing of the pol gene on plasma specimens with greater than 1000 copies per mL of HIV RNA. We identified drug-resistance mutations with the WHO list for transmitted resistance. The prevalence of sequences containing at least one drug-resistance mutation was calculated accounting for the sampling weights of the sites. We assessed the risk factors of resistance with multilevel logistic regression with random coefficients. FINDINGS 2436 (94.1%) of 2590 participants had a pretreatment genotypic resistance result. 1486 participants (57.4%) were women, 1575 (60.8%) had WHO clinical stage 3 or 4 disease, and the median CD4 count was 133 cells per μL (IQR 62-204). Overall sample-weighted drug-resistance prevalence was 5.6% (139 of 2436; 95% CI 4.6-6.7), ranging from 1.1% (two of 176; 0.0-2.7) in Pretoria, South Africa, to 12.3% (22 of 179; 7.5-17.1) in Kampala, Uganda. The pooled prevalence for all three Ugandan sites was 11.6% (66 of 570; 8.9-14.2), compared with 3.5% (73 of 1866; 2.5-4.5) for all other sites. Drug class-specific resistance prevalence was 2.5% (54 of 2436; 1.8-3.2) for nucleoside reverse-transcriptase inhibitors (NRTIs), 3.3% (83 of 2436; 2.5-4.2) for non-NRTIs (NNRTIs), 1.3% (31 of 2436; 0.8-1.8) for protease inhibitors, and 1.2% (25 of 2436; 0.7-1.7) for dual-class resistance to NRTIs and NNRTIs. The most common drug-resistance mutations were K103N (43 [1.8%] of 2436), thymidine analogue mutations (33 [1.6%] of 2436), M184V (25 [1.2%] of 2436), and Y181C/I (19 [0.7%] of 2436). The odds ratio for drug resistance associated with each additional year since the start of the ART roll-out in a region was 1.38 (95% CI 1.13-1.68; p=0.001). INTERPRETATION The higher prevalence of primary drug resistance in Uganda than in other African countries is probably related to the earlier start of ART roll-out in Uganda. Resistance surveillance and prevention should be prioritised in settings where ART programmes are scaled up. FUNDING Ministry of Foreign Affairs of the Netherlands.

[1]  M. Peeters,et al.  Antiretroviral drug resistance mutations in antiretroviral-naive patients from Senegal. , 2010, AIDS research and human retroviruses.

[2]  A. Kamali,et al.  Affordable in-house antiretroviral drug resistance assay with good performance in non-subtype B HIV-1. , 2010, Journal of virological methods.

[3]  W. Heneine,et al.  Prevalence of transmitted drug resistance associated mutations and HIV-1 subtypes in new HIV-1 diagnoses, U.S.–2006 , 2010, AIDS.

[4]  R. Lihana,et al.  HIV type 1 subtype diversity and drug resistance among HIV type 1-infected Kenyan patients initiating antiretroviral therapy. , 2009, AIDS research and human retroviruses.

[5]  S. Cassol,et al.  Molecular Characteristics of Human Immunodeficiency Virus Type 1 Subtype C Viruses from KwaZulu-Natal, South Africa: Implications for Vaccine and Antiretroviral Control Strategies , 2003, Journal of Virology.

[6]  O. Traoré,et al.  Genetic Diversity and Drug Resistance Mutations in HIV type 1 from Untreated Patients in Bamako, Mali , 2007, Antiviral therapy.

[7]  A. Tanuri,et al.  Frequency of primary resistance to antiretroviral drugs and genetic variability of HIV-1 among infected pregnant women recently diagnosed in Luanda-Angola. , 2010, AIDS research and human retroviruses.

[8]  S. Gove,et al.  The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings , 2006, The Lancet.

[9]  Erin N. Bodine,et al.  The antiretroviral rollout and drug-resistant HIV in Africa: insights from empirical data and theoretical models. , 2005, AIDS.

[10]  C. Petropoulos,et al.  High prevalence of antiretroviral resistance in treated Ugandans infected with non-subtype B human immunodeficiency virus type 1. , 2004, AIDS research and human retroviruses.

[11]  Edward P Acosta,et al.  Preexisting resistance to nonnucleoside reverse-transcriptase inhibitors predicts virologic failure of an efavirenz-based regimen in treatment-naive HIV-1-infected subjects. , 2008, The Journal of infectious diseases.

[12]  M. Wainberg,et al.  Public health implications of antiretroviral therapy and HIV drug resistance. , 1998, JAMA.

[13]  M. Peeters,et al.  Low prevalence of HIV type 1 drug resistance mutations in untreated, recently infected patients from Burkina Faso, Côte d'Ivoire, Senegal, Thailand, and Vietnam: the ANRS 12134 study. , 2009, AIDS research and human retroviruses.

[14]  D. Eric,et al.  Genetic characterization of HIV-1 strains in Togo reveals a high genetic complexity and genotypic drug-resistance mutations in ARV naive patients. , 2009, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.

[15]  L. Morris,et al.  Characterization of human immunodeficiency virus type 1 from a previously unexplored region of South Africa with a high HIV prevalence. , 2005, AIDS research and human retroviruses.

[16]  E. Arts,et al.  Molecular Characterization of Human Immunodeficiency Virus Type 1 (HIV-1) and HIV-2 in Yaoundé, Cameroon: Evidence of Major Drug Resistance Mutations in Newly Diagnosed Patients Infected with Subtypes Other than Subtype B , 2007, Journal of Clinical Microbiology.

[17]  R. Salamon,et al.  HIV-1 antiretroviral drug resistance in recently infected patients in Abidjan, Côte d'Ivoire: A 4-year survey, 2002-2006. , 2007, AIDS research and human retroviruses.

[18]  Robert J. Gifford,et al.  The calibrated population resistance tool: standardized genotypic estimation of transmitted HIV-1 drug resistance , 2009, Bioinform..

[19]  T. F. Rinke de Wit,et al.  COHORT PROFILE Cohort Profile: The PharmAccess African , 2022 .

[20]  W. Sugiura,et al.  Molecular epidemiology of HIV type 1 in treatment-naive patients in north Ethiopia. , 2007, AIDS research and human retroviruses.

[21]  Tulio de Oliveira,et al.  An automated genotyping system for analysis of HIV-1 and other microbial sequences , 2005, Bioinform..

[22]  R. Salamon,et al.  Presence of key drug resistance mutations in isolates from untreated patients of Abidjan, Côte d'Ivoire: ANRS 1257 study. , 2003, AIDS research and human retroviruses.

[23]  H. Fleury,et al.  Increasing HIV type 1 polymorphic diversity but no resistance to antiretroviral drugs in untreated patients from Central African Republic: a 2005 study. , 2006, AIDS research and human retroviruses.

[24]  M. Kozal,et al.  Prevalence of antiretroviral drug resistance mutations in chronically HIV-infected, treatment-naive patients: implications for routine resistance screening before initiation of antiretroviral therapy. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[25]  A. Puren,et al.  Antiretroviral drug resistance surveillance among drug-naive HIV-1-infected individuals in Gauteng Province, South Africa in 2002 and 2004 , 2008, Antiviral therapy.

[26]  angesichts der Corona-Pandemie,et al.  UPDATE , 1973, The Lancet.

[27]  M. Soares,et al.  Molecular diversity and polymerase gene genotypes of HIV-1 among treatment-naïve Cameroonian subjects with advanced disease. , 2010, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[28]  Anne-Mieke Vandamme,et al.  Drug Resistance Mutations for Surveillance of Transmitted HIV-1 Drug-Resistance: 2009 Update , 2009, PloS one.

[29]  N. Taveira,et al.  HIV-1 Genetic Diversity and Transmitted Drug Resistance in Health Care Settings in Maputo, Mozambique , 2009, Journal of acquired immune deficiency syndromes.

[30]  W. Wester,et al.  HIV-1 Subtype C Drug-Resistance Background among ARV-Naive Adults in Botswana , 2005, Antiviral chemistry & chemotherapy.

[31]  A. Harrison,et al.  A statistical model for HIV-1 sequence classification using the subtype analyser (STAR) , 2005, Bioinform..

[32]  K. Kamoto,et al.  Surveillance of transmitted HIV drug resistance with the World Health Organization threshold survey method in Lilongwe, Malawi , 2007, Antiviral therapy.

[33]  P. Weidle,et al.  Assessment of a pilot antiretroviral drug therapy programme in Uganda: patients' response, survival, and drug resistance , 2002, The Lancet.

[34]  Mark Myatt,et al.  Recommendations for surveillance of transmitted HIV drug resistance in countries scaling up antiretroviral treatment , 2008, Antiviral therapy.

[35]  M. Poljak,et al.  Transmission of drug-resistant HIV-1 is stabilizing in Europe. , 2009, The Journal of infectious diseases.

[36]  T. F. Rinke de Wit,et al.  HIV-1 Drug Resistance Mutations Are Present in Six Percent of Persons Initiating Antiretroviral Therapy in Lusaka, Zambia , 2010, Journal of acquired immune deficiency syndromes.

[37]  F. Raffi,et al.  European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of HIV‐infected adults , 2008, HIV medicine.

[38]  M. Peeters,et al.  Evaluation of transmitted HIV drug resistance among recently-infected antenatal clinic attendees in four Central African countries , 2008, Antiviral therapy.

[39]  D. Katzenstein,et al.  TREAT Asia Quality Assessment Scheme (TAQAS) to standardize the outcome of HIV genotypic resistance testing in a group of Asian laboratories. , 2009, Journal of virological methods.

[40]  C. Tremblay,et al.  High level of primary drug resistance in Mali , 2010, HIV medicine.

[41]  L. Palombi,et al.  Subtype analysis and mutations to antiviral drugs in HIV‐1‐infected patients from Mozambique before initiation of antiretroviral therapy: Results from the DREAM programme , 2005, Journal of medical virology.

[42]  B. Stilwell,et al.  Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. 2006 revision. , 2006 .

[43]  G. Boiteau,et al.  J. Virol. Methods , 1996, Journal of Virological Methods.

[44]  Adeeba Kamarulzaman,et al.  AIDS Res Hum Retroviruses , 2006 .

[45]  A. Tanuri,et al.  Genotypic and phenotypic characterization of human immunodeficiency virus type 1 isolates circulating in pregnant women from Mozambique , 2008, Archives of Virology.

[46]  Amalio Telenti,et al.  Antiretroviral Treatment of Adult HIV Infection2010 Recommendations of the International AIDS Society–USA Panel , 2010 .

[47]  J. Kahn,et al.  Time trends in primary HIV-1 drug resistance among recently infected persons. , 2002, JAMA.

[48]  A. Kamali,et al.  Transmitted HIV type 1 drug resistance among individuals with recent HIV infection in East and Southern Africa. , 2011, AIDS research and human retroviruses.

[49]  C. Rogier,et al.  Antiretroviral Drug Resistance among Drug-Naive HIV-1-Infected Individuals in Djibouti (Horn of Africa) , 2005, Antiviral therapy.

[50]  P. Klenerman,et al.  Prevalence of HIV type-1 drug-associated mutations in pre-therapy patients in the Free State, South Africa , 2009, Antiviral therapy.

[51]  D. Bennett,et al.  Surveillance of transmitted HIV drug resistance among women attending antenatal clinics in Dar es Salaam, Tanzania , 2008, Antiviral therapy.

[52]  M. Peeters,et al.  HIV-1 Drug-Resistance Mutations among Newly Diagnosed Patients before Scaling-Up Programmes in Burkina Faso and Cameroon , 2005, Antiviral therapy.

[53]  Douglas D. Richman,et al.  Antiretroviral Treatment of Adult HIV Infection , 2008 .

[54]  David Dunn,et al.  Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. , 2011, The Lancet. Infectious diseases.

[55]  D. Richman,et al.  Persistence of Transmitted Drug Resistance among Subjects with Primary Human Immunodeficiency Virus Infection , 2008, Journal of Virology.

[56]  M. Peeters,et al.  HIV type 1 diversity and antiretroviral drug resistance mutations in Burundi. , 2007, AIDS research and human retroviruses.

[57]  B. Masquelier,et al.  Prevalence of resistance to nevirapine in mothers and children after single-dose exposure to prevent vertical transmission of HIV-1: a meta-analysis. , 2007, International journal of epidemiology.

[58]  Michael Monsour,et al.  Minority HIV-1 Drug Resistance Mutations Are Present in Antiretroviral Treatment–Naïve Populations and Associate with Reduced Treatment Efficacy , 2008, PLoS medicine.

[59]  H. Kräusslich,et al.  Analysis of the diversity of the HIV‐1 pol gene and drug resistance associated changes among drug‐naïve patients in Burkina Faso , 2009, Journal of medical virology.

[60]  W. Preiser,et al.  Phylogenetic diversity and low level antiretroviral resistance mutations in HIV type 1 treatment-naive patients from Cape Town, South Africa. , 2008, AIDS research and human retroviruses.

[61]  O. Laeyendecker,et al.  Antiretroviral drug susceptibility among drug-naive adults with recent HIV infection in Rakai, Uganda. , 2009, AIDS.

[62]  J. Corbeil,et al.  Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy , 1994, Journal of virology.

[63]  Klaus Korn,et al.  Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. , 2005, The Journal of infectious diseases.

[64]  P. Kaleebu,et al.  Transmitted antiretroviral drug resistance surveillance among newly HIV type 1-diagnosed women attending an antenatal clinic in Entebbe, Uganda. , 2008, AIDS research and human retroviruses.

[65]  M. Peeters,et al.  HIV type 1 pol gene diversity and antiretroviral drug resistance mutations in the Democratic Republic of Congo (DRC). , 2006, AIDS research and human retroviruses.

[66]  Klaus Korn,et al.  The Calculated Genetic Barrier for Antiretroviral Drug Resistance Substitutions Is Largely Similar for Different HIV-1 Subtypes , 2006, Journal of acquired immune deficiency syndromes.

[67]  Summary TOWARDS UNIVERSAL ACCESS : Scaling up Priority HIV / AIDS Interventions in the Health Sector Progress Report , 2008 .

[68]  Lynn Morris,et al.  Impact of HIV-1 Subtype and Antiretroviral Therapy on Protease and Reverse Transcriptase Genotype: Results of a Global Collaboration , 2005, PLoS medicine.

[69]  B. Clotet,et al.  Thymidine Analogue Mutation Profiles: Factors Associated with Acquiring Specific Profiles and their Impact on the Virological Response to Therapy , 2005, Antiviral therapy.

[70]  J. Church,et al.  ANTIRETROVIRAL-DRUG RESISTANCE AMONG PATIENTS RECENTLY INFECTED WITH HIV , 2003, Pediatrics.

[71]  T. F. Rinke de Wit,et al.  Transmitted antiretroviral drug resistance among newly HIV-1 diagnosed young individuals in Kampala , 2011, AIDS.

[72]  S. Hammer,et al.  Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel. , 1997, JAMA.

[73]  Sabine Yerly,et al.  Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis. , 2009, The Lancet. Infectious diseases.